Field labs saved from ORA ax
This article was originally published in The Silver Sheet
Executive Summary
FDA's Office of Regulatory Affairs (ORA) is backing off plans to close seven field labs as part of an ongoing reorganization. Associate Commissioner for Regulatory Affairs Margaret O'K. Glavin sent ORA staff an e-mail Aug. 17 that said she was "canceling plans for the rollout of all changes in our organizational structure." However, she said this move would provide "additional time" to "take a fresh look at the challenges facing" the office. ORA's field labs inspect and analyze devices, food, drugs, animal medications and feeds, and other health products. The decision to call off the closure of seven of the office's 13 field labs was first indicated in an Aug. 1 e-mail to staff
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.